kemia; hematopoietic chimerism; relapse; immunotherapy Allogeneic hematopoietic cell transplantation (alloHCT) is performed with increasing frequency in children suffering from malignant and nonmalignant diseases. Despite recent developments, disease progression and graft rejection remain prominent causes of treatment failure. [1] [2] [3] [4] Patients who relapse after alloHCT have dismal prognoses with no effective treatment strategy available. 5 Second transplantation involves a high risk of toxic complications as well as subsequent relapse. 6, 7 Immunotherapy with donor-derived immunocompetent cells is an option for some patients relapsing after alloHCT. In patients with CML, donor lymphocyte infusions (DLI) are capable of inducing durable remissions. 8, 9 The efficacy of DLI depends upon tumor burden present at the time of infusion. Patients with cytogenetic relapse of CML are more prone to respond than those with a frank hematological recurrence. 10 The efficacy of immune intervention initiated in patients with acute leukemias relapsing after alloHCT is unclear. [11] [12] [13] Prophylactic DLI may prevent treatment failure in some patients. However, it may put others at unnecessary risk of severe graft-versus-host disease (GvHD). 14 Hematopoietic chimerism monitoring with a semiquantitative PCR-based amplification of short tandem repeats is a useful tool for engraftment monitoring. When used sequentially at the shortest intervals possible, it can identify patients with a very high risk of treatment failure. Children with an increasing number of host-derived cells (increasing mixed chimerism, inMC) have the highest risk of either graft rejection or relapse. [15] [16] [17] [18] Encouraged by these results we have asked the question whether it would be possible to prevent relapse or rejection in children with an increasing amount of autologous DNA by prompt immunotherapy together with the withdrawal of immunosuppression or DLI.
Materials and methods

Patients
Immunotherapy was introduced in 14 children with an increasing amount of host DNA detected after alloHCT. Detailed clinical characteristics of the children, including age, gender, diagnosis, donor, conditioning regimen and GvHD prophylaxis, are presented in 
Sample collection
Hematopoietic chimerism was assessed in peripheral blood mononuclear cells (PBMNCs). Blood samples were collected weekly after engraftment until discharge from hospital, and then monthly. When autologous cells were detected in PB, the bone marrow (BM) was harvested. Mononuclear cells were isolated from blood and marrow samples by density gradient centrifugation.
Methods
The chimerism status was determined by a PCR amplification of four specific STR loci: D11S533, 19 D17S30, 20 D1S111and 21 ApoB. 22 Pre-transplant samples from the donor and the recipient were processed first in order to identify the most informative locus. The PCR-STR technique is described in detail elsewhere. 23 Briefly, DNA was extracted from samples using a commercially available QIAmp blood mini kit (Qiagen, Hilden, Germany). All primers were labeled with a fluorescent dye Cy5.0 (TiB Molbiol, Poznan, Poland). PCR was performed in a final volume of 25 ml containing 250 ng of DNA, 2.5 ml PCR buffer (Qiagen), 1.5 mM MgCl 2 , 200 mM dNTP (Qiagen), 2.5 U HotStart TAQ polymerase (Qiagen) and 1 mM of primer (TiB Molbiol, Poznan, Poland). PCR cycling parameters were as follows: initial 15 min pre-heating at 951C, denaturation at 941C for 1 min 30 s, annealing for 45 s (661C for D11S533 and D1S111, 601C for D17S30 and 581C for ApoB) and elongation at 721C for 2 min for 35 cycles followed by a final extension step at 721C for 30 min (Peltier thermal cycler PTC-200, MJ Research, USA). Amplified VNTR loci were separated and detected with OpenGene automated DNA sequencer (Visible Genetics, Toronto, Canada). PCR products were diluted 1:2 in formamide loading dye solution (Visible Genetics), heat denatured at 951C for 5 min and placed on ice. A Surefill 6% sequencing gel (Visible Genetics) was used. After denaturation, 2 ml of diluted PCR product was loaded on the gel and run for 60 min at 1300 V, 20% laser power at 531C. Each post transplant sample was analyzed in parallel with the autologous and allogeneic control. This approach allowed for an unambiguous identification of the host-and donor-specific peaks. The analysis of the data was performed with OpenGene software.
Quantitative measurement of mixed chimerism
The calculation of the percentage of autologous cells was based on an assumption that the amount of DNA reflected the number of cells present in the sample, and that the donor's and the recipient's alleles amplified with a similar efficacy. STR loci were classified as informative if a separate host-specific peak resulting from the amplification of a host-specific allele was identified. The area of the fluorescent peak detected by the sequencer corresponded to the number of dye molecules. Assuming that each amplified fragment had only one dye particle attached, the area of the fluorescent peak corresponded directly to the number of fragments present in the PCR product and not to the length of the fragment. Therefore, no standard curve preparation was necessary and calculations of the percentage of autologous cells were performed according to the formulas outlined in Figure 1 .
Forms of immune intervention and definition of response
In patients with increasing mixed chimerism in PBMNCs, the BM was aspirated to evaluate remission and to assess the chimerism status in BMMNCs. If the criteria for hematological remission were not fulfilled, patients were tapered off cyclosporine A (CsA) immediately and received debulking chemotherapy to decrease tumor load. If CR was maintained, the immune intervention depended upon immunosuppression at the time of MC detection. The patients still receiving CsA had immunosuppression withdrawn immediately. Those without CsA received DLI as the first-line treatment. The chimerism evaluation was performed weekly after the initiation of the therapy. The response was defined as a continuous decrease in the autologous signal in subsequent chimerism assessments, a conversion to CC, and maintaining or achieving remission. If the front-line treatment was ineffective and GvHD was not present, DLI was repeated or introduced in children who had CsA withdrawn first. A detailed diagram of the decision-making process is presented in Figure 2 .
Definition of increasing mixed chimerism
InMC was defined as at least 5% increase in the amount of autologous DNA between two consecutive assessments.
GvHD grading
GvHD was assessed and graded according to Klingebiel et al. 24 
Results
Response to first-line treatment
Immune therapy was initiated in 14 patients with inMC. Two of them (UPN 178 and UPN 242) relapsed at the time of inMC detection. Both had CsA withdrawn. UPN 242 received low-dose cyclophosphamide (200 mg total dose) and vincristine (1.5 mg/m 2 ). Both developed grade III GvHD (skin þ gut), which required treatment with methylprednisolone. They achieved remission and converted to CC. UPN 178 experienced rapid disease progression despite cessation of CsA. The patient received two FLAG courses and was transplanted from the same donor with PBPCs, fludarabine and L-PAM in conditioning and low-dose CsA as GvHD prophylaxis. At 20 days after the second transplantation, inMC was detected again and CsA was withdrawn with no response. The child progressed to overt hematological relapse and was scheduled for DLI, but the parents refused further treatment.
In total, 12 children were still in remission at the time of inMC. Nine were still on CsA and had immunosuppression withdrawn immediately. Seven of them responded to CsA cessation and converted to CC. Five remain in CR, one (UPN 199) relapsed in CNS despite CC status both in PB and BM, and one died due to interstitial pneumonia. UPN 236 did not respond and had rejected the graft before DLI. The patient developed pulmonary aspergillosis, underwent a second transplant but died on day þ 59 due to acute renal failure and pulmonary edema secondary to Immunotherapy in children with mixed chimerism after alloHCT E Gorczyñska et al abdominal aortal thrombosis. UPN 181 did not respond to CsA withdrawal, but remained in hematological remission and was scheduled for DLI.
Three patients received DLI as the front-line treatment. UPN 149 was transfused with 5 Â 10 5 T lymphocytes/ kg, and in the remaining two children T-cell dose was limited to 5 Â 10 4 /kg. UPN 238 responded and converted to CC. The response was transient and inMC reappeared on day þ 120. The parents refused further treatment and the child relapsed. UPN 149 and UPN 209 did not respond and were scheduled for the second DLI (see Table 2 ).
Response to second-line treatment
Three patients, in whom the first-line treatment had been ineffective, received the second-line therapy. UPN 181 received 1 Â 10 7 /kg T lymphocytes, converted to CC and remains alive in remission with no symptoms of GvHD. In UPN 149, DLI was repeated with an increased dose of T lymphocytes (1 Â 10 6 /kg). The patient converted to CC and remains alive in remission. She developed acute grade III GvHD (skin þ liver) at some stage; however, she responded to a methylprednisolone treatment. UPN 209 was transfused with 1 Â 10 5 /kg lymphocytes and responded with a decrease in the amount of autologous DNA. She remains in remission with a low level of autologous DNA detectable and grade I/II skin GvHD (see Table 3 ).
GvHD and immune therapy-related toxicity
Children with inMC were scheduled for immunotherapy only if no GvHD symptoms were present. Clinically important grade II-IV acute GvHD was a common complication and occurred in nine out of 14 patients: in seven after CsA withdrawal, in one after DLI as the frontline treatment, and in one after DLI as the second-line therapy. All patients with clinically significant GvHD received immunosuppressive treatment with methylprednisolone and CsA with good response. No GvHD -related death was noted. One child (UPN 209) developed transient acute grade I skin GvHD after the second DLI that resolved without treatment. Chronic GvHD occurred in three patients. Two of them were treated with CsA and steroids, one (UPN 242) was left untreated due to a high risk of relapse (the patient who responded to CsA withdrawal in hematological recurrence). No pancytopenia or marrow suppression secondary to the immune therapy occurred.
GvHD and response
Only two out of 12 patients who responded to immunotherapy did not demonstrate concomitant features of GvHD, whereas GvHD was absent in 'nonresponders' group. In patient UPN 238, the initial response correlated with an onset of acute GvHD requiring therapy with methylprednisolone. GvHD resolved completely, but the patient developed inMC again and subsequently relapsed. Immunotherapy in children with mixed chimerism after alloHCT E Gorczyñska et al
Discussion
The therapeutic potential of alloHCT has two main contributors -the conditioning regimen and the antileukemic activity of donor-derived lymphocytes. T-cell depletion of the graft leads to an increased incidence of leukemia relapse, whereas GvHD has a protective effect against disease recurrence. 25, 26 GvHD prophylaxis, necessary to decrease treatment-related mortality, can profoundly impair the graft-versus-leukemia effect. 27 Enhancement of the allogeneic lymphocyte function is possible after abrupt cessation of immunosuppression 28 or, in patients not receiving immunosuppression, by infusion of donor lymphocytes. 29 However, the efficacy of immunotherapy initiated after frank hematological relapse is limited. In CML, donor lymphocytes are more effective if infused at the time of cytogenetic relapse, before the leukemic clone expands. 30 Sequential monitoring of hematopoietic chimerism may identify patients at the highest risk of incipient treatment failure while the tumor burden is limited [11] [12] [13] . In our study, we tried to amplify the antileukemic activity of donor-derived lymphocytes in children with inMC detected after allogeneic HCT. We adopted a decision-making algorithm originally proposed by Bader et al. 31 Children without remission at the time of inMC detection were not included into the algorithm. However, in a proportion of patients, the sequential chimerism monitoring failed to detect treatment failure and inMC was detected along with overt clinical relapse. We decided to offer such children a chance of cure with immunotherapy. Cellular responses necessary to eradicate the expanding leukemic clone require time to develop and might be incapable of overcoming bulky disease. In order to decrease the tumor load, patients with hematological relapse received 'debulking' chemotherapy, together with abrupt cessation of immunosuppression -an approach applied with some success by others. 32 This strategy resulted in conversion to CC and achievement of remission in one out of two patients treated in relapse. The response correlated with an emergence of severe acute GvHD, which resolved after treatment with steroids. The child remains alive and well with no evidence of disease, but with symptoms of chronic GvHD, which may be necessary for a long-term disease control. 33 CsA withdrawal can induce remissions in relapsed CML patients, but has been reported to have a limited efficacy in recurrent acute lymphoblastic leukemia. 34 Of nine patients with acute lymphoblastic leukemia (ALL) who had immunosuppression withdrawn as the front-line treatment, seven responded and converted to complete donor-type chimeras. Two additional ALL patients achieved CC after DLI, which has also been reported to have a limited efficacy in relapsed acute leukemia. 35 An unexpectedly high response rate in children with ALL, as well as in children with other malignancies, can be explained by an early initiation of immunotherapy in patients with a low tumor burden. The question of whether autologous cells detected by chimerism monitoring are leukemic or represent residual autologous hematopoiesis may not be crucial. InMC may indicate a state of tolerance and lack of GvL, an effect favoring the expansion of residual leukemia. The tolerance can be reversed by an immune intervention according to the proposed protocol. Re-established GvL prevents leukemia from progressing.
Three patients had no immunosuppression when inMC was detected. All received DLI as the front-line treatment. The optimal dose of T lymphocytes infused is still a matter of debate. 36 We tried to keep a balance between potential benefits (prevention of leukemia relapse) and the risk of life threatening GvHD. All patients who received DLI as the front-line treatment were transplanted from HLA-mismatched family donors. Since HLA mismatch increases the risk of GvHD, we decided to infuse limited numbers of allogeneic lymphocytes (1 Â 10 4 /kg bw). However, in UPN 149, the percentage of autologous cells was increasing rapidly along with deterioration of the grafted marrow function. Early T-cell recovery in the context of T-cell depletion, inMC and deteriorating graft function suggested autologous origin of T lymphocytes detected in the patient. Therefore, we decided to increase the initial dose of lymphocytes to 5 Â 10 5 /kg. One child responded and two others required additional DLI with an increased dose of T lymphocytes to produce a response. A complication that has been reported to occur occasionally after DLI is pancytopenia. 12 None of our patients developed marrow aplasia after DLI. The explanation may be functional donor hematopoiesis at the time of DLI. Aplasia is the aftermath of the eradication of an autologous marrow by infused donor lymphocytes and develops when a grafted marrow function is lacking. 37 Our data suggest the presence of a positive correlation between the response and GvHD. Only one patient eliminated autologous cells without concomitant features of GvHD. Patients who failed to convert to CC had no features of GvHD. In one patient an initial response correlated with the onset of GvHD requiring treatment with steroids. GvHD resolved and the resolution of GvHD was accompanied by the reappearance of an autologous signal and the final progression to relapse. Our results do not necessarily indicate that successful GvL require GvHD. The results may just reflect the fact that immunotherapy can induce both processes, and that an effective treatment of GvHD may lead to the inhibition of the antileukemic activity of allogeneic lymphocytes. The efficacy of immunotherapy did not correlate with the severity of GvHD. One patient relapsed in CNS despite a prior conversion to CC in both PB and BM. This may indicate that CNS can be a sanctuary for leukemic cells leaving them beyond the reach of not only chemotherapy, but also allogeneic lymphocytes.
In conclusion, chimerism-guided immunotherapy according to a schedule proposed by Bader et al 31 results in a high response rate with conversion to full-donor chimerism in a majority of patients, even those with ALL. The toxicity is limited to a GvHD that can be a life-threatening complication, but can be treated successfully with steroids. Patients who fail to respond to the firstline treatment may still be salvaged by the second-line therapy. However, responses can be transient and the leukemic clone may reappear especially if immunotherapyinduced GvHD requires treatment with steroids. Our results are encouraging and warrant future studies.
